The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Jet2 swings to loss; Hyve Group sees busiest quarter

Thu, 08th Jul 2021 11:38

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Jet2 PLC - Yeadon, England-based airline and package holiday operator - Swings to a pretax loss of GBP369.9 million in the year ended March 31 from a profit of GBP147.7 million a year prior. Revenue sinks to GBP395.4 million from GBP3.58 billion. Single sector passengers flown comes in at 1.3 million, falling sharply from 14.6 million the year before. "Extensive restrictions on international travel imposed by the UK Government, meant our aircraft fleet was fully grounded for approximately 29 weeks of the financial year and operated with a significantly reduced programme when flying was permitted," says company. Does not declare a final dividend, unchanged from last year, given "the ongoing impact of Covid-19". This leaves shareholder's pockets empty for the year, compared to a total payout of 3.0 pence a year ago. "Group performance for the financial year ending March 31, 2022 is very much dependent on the level of flying permitted for the remainder of summer 2021 and performance in the second half of the financial year, periods for which we still have limited visibility. Unsurprisingly given the continuing short-term uncertainty, customers are booking significantly closer to departure for summer 2021; and, although bookings to date for [this coming winter] are satisfactory, they have slowed more recently given the ongoing speculation around international travel," says company.

----------

Hyve Group PLC - London-based exhibitions and conferences organiser - Says the third quarter to end June "has been the group's busiest trading quarter since the Covid-19 pandemic began". Says 18 in-person events ran over the quarter, bringing the total number for the year to date to 28. The increased number of events reflects the continued momentum across the group's Eastern markets, primarily Russia, China, Turkey and Ukraine, company says. "[The third quarter] is traditionally a strong trading period for the group and it is extremely encouraging that Hyve has successfully run more events in the quarter than in the entirety of the first half. Many of the group's key markets in the East have been open for a number of months now and, combined with the continued pace of the vaccine rollout in our Western markets, this gives the group continued confidence when looking ahead to the final quarter of [the 2021 financial year] and beyond," CEO Mark Shashoua says.

----------

Fuller, Smith & Turner PLC - London-based pub and hotel company - Reports pretax loss of GBP57.8 million in the year to March 27, swinging from a profit of GBP8.4 million a year ago. Revenue plummets to GBP73.2 million from GBP316.0 million due to the enforced closure of social businesses throughout the year. "No full year dividend proposed in light of pandemic impact on trading performance, but intention to return to progressive dividend policy at the appropriate time," says company. Did not pay a final dividend a year prior. "The boom in staycations and desire to get back out with friends has led to strong trading in parts of our estate - particularly Cotswold Inns & Hotels and our rural pubs with rooms - and there is an incredibly busy season to come with numerous weddings and a high level of advance bookings," says Chief Executive Simon Emeny. Aims at "sustainable returns for the long term".

----------

Equals Group PLC - London-based payments and e-banking firm - Says revenue for the first half to June 30 is up 21% to GBP16.7 million from GBP13.8 million a year ago, "despite the continued absence of meaningful travel-related activity". "The hard work undertaken on both product development and cost restructuring over the last twelve months has really paid off as can be seen from these excellent revenues for [the second half of] 2021. Given the growth trajectory, we remain highly confident about the revenue prospects for second half of the year," says CEO Ian Taylor.

----------

ReNeuron Group PLC - Pencoed, Wales-based developer of cell-based therapeutics - Posts pretax loss for the year to end March of GBP13.4 million, narrowing from GBP13.9 million. Revenue falls sharply to GBP257,000 from GBP6.1 million. Revenue mostly comes from royalties from non-therapeutic licensing activities and income from research collaboration activities. Research development costs fall 41% to GBP9.5 million from GBP16.3 million. "Our decision in 2020 to focus the Company's resources on our retinal disease programme and our exosome and iPSC platforms has resulted in significantly lower operating costs, as reflected in the results for the year," says CEO Olav Hellebo. Looks forward to "data-driven potential value inflection points" over the next 12 months.

----------

JPMorgan Global Core Real Assets Ltd - real estate, transportation and infrastructure investor - Posts net asset value per share at February 28 of 87.9p, tumbling 9.1% from 96.8p a year ago. Pretax loss widens to GBP12.7 million from GBP4.7 million. Annual payout stands at 3.25p per share. Last year, the firm paid a maiden interim dividend of 0.75p per share. "The directors intend to maintain the current level of dividend payments and review the level of dividend cover in the coming quarter...Your board is hopeful that over the longer term the success of the underlying businesses into which we invest will facilitate a steadily growing level of dividends." says company. Says it has weathered the pandemic and the only headwind is "the current strength of pound sterling relative to most foreign currencies, an issue which many regard as a 'high quality problem'".

----------

Yu Group PLC - Nottingham, England-based supplier of gas, electricity and water to the UK business market - Says it has made a "very strong" start to the year and expects the positive momentum to continue. In the six months to end June, revenue is expected to increase 42% to GBP65.0 million from GBP45.9 million a year ago. Says it is confident it will meet market expectations for the year. Expects to report a strong earnings before interest, tax, depreciation and amortisation performance for the year, with further improvement into 2022 as "the group benefits from high scale benefits and its digital roll out".

----------

Mpac Group PLC - Coventry, England-based packaging company - Says the strong momentum in the second half of 2020 has continued into the first half of 2021. In the first half of 2021, order intake has been "significantly above" the Covid-impacted first half of 2020. Says it is comfortable with current full year market expectations. "I am pleased to report a strong start to 2021 across all regions. The outlook is positive based on trends in new prospects and customer investment discussions, and we enter the second half of 2021 with both a strong order book and a developing prospect pipeline and we remain confident that we can leverage the One Mpac operating model to deliver sustainable profitability," says CEO Tony Steels.

----------

InnovaDerma PLC - London-based developer of beauty, personal care and life science products - Says despite Covid-19 headwinds, revenues for the year have performed broadly in line with expectations. Expects revenue for year to end June of no less than GBP10.2 million, down 23% from GBP13.3 million last year. Believes that future prospects will improve once Covid-19 restrictions are lifted and social norms return. Expects to return to profitability for the year to end June 2022.

----------

Surface Transforms PLC - Liverpool-based maker of carbon‐ceramic automotive brake discs - Says revenue in first half of 2021 grows 34% to GBP1.2 million from GBP900,000 a year prior, exceeding managements' original expectations. Says revenue is expected to increase further in the final quarter of 2021 following the start of production on the multi-year original equipment manufacturing contracts.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
23 Nov 2021 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Nov 2021 12:20

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

Read more
26 Oct 2021 19:06

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Read more
26 Oct 2021 14:02

ReNeuron enters cancer therapy collaboration with UCL

(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.

Read more
21 Oct 2021 16:40

Director dealings: Reneuron Group non-executive makes share purchase

(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.

Read more
21 Oct 2021 14:07

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:14

ReNeuron treats first Oxford patient as part of expanded study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.

Read more
11 Oct 2021 11:51

ReNeuron upbeat on positive data from Spain collaboration

(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more
11 Oct 2021 11:05

IN BRIEF: ReNeuron gets positive results from exosome drug data

IN BRIEF: ReNeuron gets positive results from exosome drug data

Read more
11 Oct 2021 10:59

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Read more
1 Oct 2021 11:15

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

Read more
1 Oct 2021 10:33

ReNeuron gets approval to restart RP clinical study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.

Read more
9 Sep 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
6 Aug 2021 10:55

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.